PET Metabolic Biomarkers for Cancer.
The body's main fuel sources are fats, carbohydrates (glucose), proteins, and ketone bodies. It is well known that an important hallmark of cancer cells is the overconsumption of glucose. Positron emission tomography (PET) imaging using the glucose analog (18)F-fluorodeoxyglucose ((18)F-FDG) has been a powerful cancer diagnostic tool for many decades. Apart from surgery, chemotherapy and radiotherapy represent the two main domains for cancer therapy, targeting tumor proliferation, cell division, and DNA replication-all processes that require a large amount of energy. Currently, in vivo clinical imaging of metabolism is performed almost exclusively using PET radiotracers that assess oxygen consumption and mechanisms of energy substrate consumption. This paper reviews the utility of PET imaging biomarkers for the detection of cancer proliferation, vascularization, metabolism, treatment response, and follow-up after radiation therapy, chemotherapy, and chemotherapy-related side effects.
National Cardiac PET Centre, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Etienne
E
Croteau
National Cardiac PET Centre, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Jennifer M
JM
Renaud
Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada.
Marie Anne
MA
Richard
National Cardiac PET Centre, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Terrence D
TD
Ruddy
Division of Nuclear Medicine, Department of Radiology, University of British Columbia, Vancouver, BC, Canada.
François
F
Bénard
National Cardiac PET Centre, Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
Robert A
RA
deKemp
FDG; cardiotoxicity; metabolism; oncology; perfusion; positron emission tomography; radiotherapy
Am J Nucl Med Mol Imaging. 2014 Jun 07;4(4):365-84
24982822
J Nucl Med. 1997 Apr;38(4):617-24
9098213
Cancer Lett. 2015 Jan 28;356(2 Pt A):211-6
24569091
Radiology. 2014 Mar;270(3):849-56
24475804
Cancer J. 2015 Mar-Apr;21(2):129-36
25815854
Semin Oncol. 2008 Jun;35(3):211-20
18544436
Oncologist. 2008 Jun;13(6):631-44
18586918
Mol Cancer Ther. 2011 Dec;10 (12 ):2215-23
22161785
Semin Cell Dev Biol. 2012 Jun;23 (4):352-61
22406683
Prog Urol. 2002 Feb;12(1 Suppl 2):19-30
11980024
Radiographics. 2003 Mar-Apr;23 (2):315-40; quiz 533
12640150
Mol Imaging Biol. 2006 Jul-Aug;8(4):237-44
16791750
PLoS One. 2012;7(12):e51020
23236419
Eur J Nucl Med Mol Imaging. 2002 Dec;29(12 ):1617-22
12458396
Sci Transl Med. 2013 May 29;5(187):187ra69
23720580
Curr Pharm Biotechnol. 2013;14(3):300-12
23597406
Indian J Pharmacol. 2013 Jan-Feb;45(1):44-8
23543849
Cancer Metastasis Rev. 2014 Mar;33(1):217-29
24436017
Heart. 2001 Aug;86(2):219
11454849
Am J Nucl Med Mol Imaging. 2012;2(1):33-47
23133801
Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263
18980023
Cancer Discov. 2012 Oct;2(10):881-98
23009760
J Nucl Med. 2008 Nov;49(11):1763-8
18927324
Int J Cancer. 2014 Oct 1;135(7):1711-20
24615175
Pulm Circ. 2013 Jan;3(1):144-52
23662191
Nucl Med Commun. 2016 Mar;37(3):239-46
26588068
Curr Hypertens Rep. 2010 Dec;12(6):404-10
20842465
Physiol Rev. 2010 Jan;90(1):207-58
20086077
Circ Res. 1989 Dec;65(6):1787-97
2684448
J Nucl Med. 2001 Aug;42(8):1174-82
11483676
Eur J Nucl Med. 2001 May;28(5):651-68
11383873
Mol Pharm. 2014 Nov 3;11(11):3852-66
25095908
Nucl Med Biol. 2004 Oct;31(7):859-65
15464387
Haematologica. 2006 Apr;91(4):482-9
16585015
Mol Imaging Biol. 2008 Jul-Aug;10 (4):217-23
18454299
Semin Oncol. 2013 Apr;40(2):168-77
23540742
Nat Rev Drug Discov. 2011 Feb;10(2):111-26
21283106
Therapie. 2004 Jan-Feb;59(1):121-6
15199678
Nucl Med Commun. 2016 Apr;37(4):348-55
26642435
Eur J Nucl Med Mol Imaging. 2004 Dec;31(12 ):1659-72
15565331
Mol Interv. 2005 Jun;5(3):163-71
15994456
Neuron. 2015 May 20;86(4):883-901
25996133
Semin Oncol. 2011 Feb;38(1):55-69
21362516
Nutr Metab (Lond). 2010 Apr 22;7:33
20412570
Clin Cancer Res. 2013 Jul 15;19(14):3905-13
23743570
Nat Rev Cancer. 2006 Sep;6(9):714-27
16929325
J Inherit Metab Dis. 2005;28(2):109-21
15877199
Br J Cancer. 2013 Apr 30;108(8):1624-33
23531700
Cancer Treat Rev. 2011 Jun;37(4):300-11
21126826
J Neurooncol. 2011 Oct;105(1):103-7
21503829
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):105-13
20728697
Arch Pharm Res. 2015 Mar;38(3):338-45
25599615
J Nucl Med. 1982 Jul;23(7):577-86
6979614
Pharmacol Rev. 2004 Jun;56(2):185-229
15169927
Cancer Metab. 2013 Feb 04;1(1):8
24280138
Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):186-97
23076620
Cancer Cell. 2008 Jun;13(6):472-82
18538731
Am J Physiol Endocrinol Metab. 2009 Sep;297(3):E578-91
19531645
Nutrition. 2011 Jan;27(1):3-20
21035308
J Neurooncol. 2003 May;62(3):329-38
12777086
Case Rep Pulmonol. 2014;2014:973573
25389506
Can J Cardiol. 2014 Aug;30(8):869-78
25064580
Eur Urol. 2011 Jan;59(1):51-60
20869161
J Nucl Med. 2008 Jun;49 Suppl 2:43S-63S
18523065
Oncol Rep. 2013 Jan;29(1):205-11
23124523
Acad Radiol. 2016 Feb;23 (2):220-36
26521689
PLoS One. 2013;8(3):e58938
23554961
Int J Cardiol. 2013 Sep 30;168(2):680-7
23639459
J Neurol Neurosurg Psychiatry. 2004 Oct;75(10 ):1457-62
15377696
Clin Nucl Med. 2015 Jun;40(6):494-5
25674864
JACC Cardiovasc Imaging. 2013 Apr;6(4):512-4
23579012
Nucl Med Biol. 2014 Nov-Dec;41(10 ):863-70
25195015
Mol Cell Biol. 2013 May;33(9):1869-82
23459938
Nat Rev Cancer. 2007 May;7(5):332-44
17457301
Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19
14769489
Cell. 2014 Dec 18;159(7):1492-4
25525870
J Nucl Med. 2008 Mar;49(3):480-508
18287273
J Neurooncol. 2006 Jun;78(2):145-51
16739028
J Thorac Oncol. 2009 Jun;4(6):722-7
19404213